Cidara Therapeutics, Inc. (CDTX)

Cidara Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020
Period Ending	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Cash & Equivalents	293.65	510.58	168.15	189.83	127.39	164.37	29.02	35.78	48.67	50.43	47.98	32.73	53.08	24.64	36.49	59.68	36.6	48.28	42.86	35.91
Short-Term Investments	126.37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash & Short-Term Investments	420.02	510.58	168.15	189.83	127.39	164.37	29.02	35.78	48.67	50.43	47.98	32.73	53.08	24.64	36.49	59.68	36.6	48.28	42.86	35.91
Cash Growth	229.72%	210.63%	479.47%	430.56%	161.73%	225.94%	-39.52%	9.31%	-8.30%	104.69%	31.48%	-45.16%	45.02%	-48.98%	-14.87%	66.18%	-19.59%	-11.93%	-33.35%	-28.56%
Accounts Receivable	1.86	1.86	1.69	1.69	1.7	2.35	7.28	14.08	2.86	5.48	25.83	5.83	5.04	4.83	8.78	5.36	3.87	3.16	0.01	11.18
Inventory	-	-	-	-	-	-	7.27	-	2.47	1.95	-	-	-	-	-	-	-	-	-	-
Other Current Assets	20.94	19.36	19	19.22	27.69	1.87	3.27	11	3.71	4.37	5.69	6.53	5.78	7.08	6.74	6.66	6.8	9.64	8.43	10.1
Total Current Assets	442.82	531.79	188.85	210.74	156.77	168.59	46.83	60.86	57.7	62.24	79.49	45.09	63.9	36.55	52.01	71.7	47.28	61.08	51.3	57.19
Net Property, Plant & Equipment	2.09	2.44	2.78	3.96	4.32	4.67	4.9	5.13	4.71	4.69	1.19	1.32	1.66	1.97	2.27	2.54	2.76	0.71	0.95	1.21
Long-Term Investments	50.16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Long-Term Assets	23.58	0.1	0.1	0.1	1.24	0.1	0.99	1.05	1.05	1.06	1.06	1.07	1.3	1.01	1.02	1.08	1.17	1.96	1.96	2.02
Total Assets	518.65	534.33	191.73	214.8	162.33	173.36	52.72	67.03	63.47	67.99	81.74	47.49	66.86	39.52	55.3	75.33	51.21	63.74	54.21	60.42
Accounts Payable	4.35	2.21	4.9	3.61	2.97	2.29	5.06	3.77	3.66	1.9	3.98	1.45	4.24	3.09	2.86	1.3	3.24	2.59	3.22	4.57
Accrued Expenses	89.93	28.62	42.48	44.3	39.79	35.82	34.58	37.25	16.23	13.6	14.92	24.13	12.28	12.03	12.31	15.06	12.49	11.55	14.71	12.17
Current Portion of Long-Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	0.37	1.48	2.59	3.7	4.81	5.92	7.02
Current Portion of Leases	1.56	1.5	1.44	1.64	1.58	1.52	1.46	1.3	1.05	0.94	1	1.21	1.28	1.23	1.19	1.15	1.03	0.48	0.72	0.94
Unearned Revenue	-	-	-	-	-	-	24.32	0.43	14.68	14.98	15.76	14.61	15.25	14.73	14.26	13.92	13.03	14.46	15.41	13.87
Other Current Liabilities	-	-	-	-	-	0.01	-	24.67	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities	95.84	32.32	48.81	49.55	44.34	39.64	65.43	67.42	35.62	31.42	35.66	41.4	33.05	31.46	32.11	34.02	33.49	33.89	39.97	38.56
Long-Term Leases	0.42	0.84	1.24	1.93	2.36	2.78	3.18	3.58	3.31	3.6	-	-	0.34	0.68	1	1.32	1.62	-	-	-
Other Long-Term Liabilities	-	-	-	-	-	-	1.89	4.25	16.5	17.55	19.24	20.53	24.4	15.35	17.23	18.41	17.25	14.07	12.35	11.15
Total Long-Term Liabilities	0.42	0.84	1.24	1.93	2.36	2.78	5.07	7.82	19.81	21.15	19.24	20.53	24.74	16.03	18.23	19.74	18.87	14.07	12.35	11.15
Total Liabilities	96.26	33.15	50.05	51.49	46.7	42.42	70.5	75.24	55.43	52.57	54.9	61.93	57.79	47.49	50.34	53.75	52.36	47.96	52.32	49.71
Common Stock	0	0	0	0	0	0	0	0	0.01	0.01	0.01	0	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0
Additional Paid-in Capital	1,166	1,162	776.42	774.57	674.58	673.9	433.98	433.22	432.32	431.52	430.59	404.06	402.65	400.6	400.4	398.73	359.2	358.07	354.88	345.41
Accumulated Other Comprehensive Income	-0.11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-743.69	-660.46	-634.74	-611.26	-558.95	-542.97	-451.76	-441.43	-424.29	-416.11	-403.76	-418.5	-393.59	-408.57	-395.45	-377.17	-360.36	-342.28	-352.99	-334.7
Shareholders' Equity	422.39	501.17	141.68	163.31	115.63	130.94	-17.78	-8.21	8.04	15.41	26.84	-14.44	9.07	-7.96	4.96	21.57	-1.16	15.79	1.89	10.72
Total Liabilities & Equity	518.65	534.33	191.73	214.8	162.33	173.36	52.72	67.03	63.47	67.99	81.74	47.49	66.86	39.52	55.3	75.33	51.21	63.74	54.21	60.42
Total Debt	1.98	2.33	2.67	3.58	3.94	4.3	4.65	4.88	4.36	4.54	1	1.21	1.62	2.28	3.68	5.06	6.35	5.29	6.63	7.96
Net Cash (Debt)	418.04	508.24	165.48	186.25	123.44	160.07	24.37	30.9	44.31	45.89	46.98	31.52	51.46	22.36	32.81	54.62	30.25	42.99	36.23	27.95
Net Cash Growth	238.65%	217.51%	578.99%	502.73%	178.57%	248.83%	-48.12%	-1.96%	-13.88%	105.27%	43.16%	-42.29%	70.09%	-48.00%	-9.43%	95.42%	-16.51%	-2.80%	-31.36%	-27.48%
Net Cash Per Share	15.55	32.69	11.67	19.15	18.90	35.07	5.37	6.83	9.82	10.19	9.28	8.77	11.62	6.47	9.63	16.94	12.21	14.49	15.43	12.66
Book Value	422.39	501.17	141.68	163.31	115.63	130.94	-17.78	-8.21	8.04	15.41	26.84	-14.44	9.07	-7.96	4.96	21.57	-1.16	15.79	1.89	10.72
Book Value Per Share	15.71	32.24	9.99	16.79	17.71	28.69	-3.92	-1.81	1.78	3.42	5.30	-4.02	2.05	-2.30	1.45	6.69	-0.47	5.32	0.81	4.85
Tangible Book Value	422.39	501.17	141.68	163.31	115.63	130.94	-17.78	-8.21	8.04	15.41	26.84	-14.44	9.07	-7.96	4.96	21.57	-1.16	15.79	1.89	10.72
Tangible Book Value Per Share	15.71	32.24	9.99	16.79	17.71	28.69	-3.92	-1.81	1.78	3.42	5.30	-4.02	2.05	-2.30	1.45	6.69	-0.47	5.32	0.81	4.85

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: Sep 30, 2025

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error